• 1
    Ashkenazi A, Pai RC, Fong S, et al . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104: 15562.
  • 2
    McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood. 1983; 62: 113.
  • 3
    Bennett JM, Young ML, Andersen JW, et al . Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997; 80: 22059.
  • 4
    Byrd JC, Mrozek K, Dodge RK, et al . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 432536.
  • 5
    Grimwade D, Walker H, Oliver F, et al . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998; 92: 232233.
  • 6
    Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005; 19: 2195202.
  • 7
    Bodmer JL, Holler N, Reynard S, et al . TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2000; 2: 2413.
  • 8
    Kischkel FC, Lawrence DA, Chuntharapai A, et al . Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000; 12: 61120.
  • 9
    Sprick MR, Weigand MA, Rieser E, et al . FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000; 12: 599609.
  • 10
    LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003; 10: 6675.
  • 11
    Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 2004; 14: 35972.
  • 12
    MacFarlane M, Kohlhaas SL, Sutcliffe MJ, et al . TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005; 65: 1126570.
  • 13
    Snell V, Clodi K, Zhao S, et al . Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997; 99: 61824.
  • 14
    Walczak H, Miller RE, Ariail K, et al . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5: 15763.
  • 15
    MacFarlane M, Inoue S, Kohlhaas SL, et al . Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 2005; 12: 77382.
  • 16
    Kelley RF, Totpal K, Lindstrom SH, et al . Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005; 280: 220512.
  • 17
    Riccioni R, Pasquini L, Mariani G, et al . TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica. 2005; 90: 61224.
  • 18
    Suh WS, Kim YS, Schimmer AD, et al . Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia. 2003; 17: 21229.
  • 19
    McLornan P, McMullin MF, Mills KI, et al . The prognostic role of c-FLIP in AML. 14th Congress of the European Hematology Association, June 4–7, 2009: Haematologica. 2009. p.pp. 108 abs. 0272.
  • 20
    van der Sloot AM, Tur V, Szegezdi E, et al . Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA. 2006; 103: 86349.
  • 21
    Holohan C, Szegezdi E, Ritter T, et al . Cytokine-induced beta-cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-XL. J Cell Mol Med. 2008; 12: 591606.
  • 22
    Mahalingam D, Keane M, Pirianov G, et al . Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer. 2009; 100: 141524.
  • 23
    Tur V, van der Sloot AM, Reis CR, et al . DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem. 2008; 283: 205608.
  • 24
    Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002; 320: 36987.
  • 25
    Schymkowitz JW, Rousseau F, Martins IC, et al . Prediction of water and metal binding sites and their affinities by using the fold-X force field. Proc Natl Acad Sci USA. 2005; 102: 1014752.
  • 26
    van der Sloot AM, Mullally MM, Fernandez-Ballester G, et al . Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. Protein Eng Des Sel. 2004; 17: 67380.
  • 27
    Thomas LR, Johnson RL, Reed JC, et al . The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem. 2004; 279: 5247986.
  • 28
    Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977; 270: 3479.
  • 29
    Matsuo Y, MacLeod RA, Uphoff CC, et al . Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9) (q23;p22p23). Leukemia. 1997; 11: 146977.
  • 30
    Ohyashiki K, Ohyashiki JH, Sandberg AA. Cytogenetic characterization of putative human myeloblastic leukemia cell lines (ML-1, -2, and -3): origin of the cells. Cancer Res. 1986; 46: 36427.
  • 31
    Quentmeier H, Martelli MP, Dirks WG, et al . Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005; 19: 17607.
  • 32
    Duiker EW, de Vries EG, Mahalingam D, et al . Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res. 2009; 15: 204857.
  • 33
    Carter BZ, Mak DH, Schober WD, et al . Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008; 111: 374250.
  • 34
    Braeuer SJ, Buneker C, Mohr A, et al . Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res. 2006; 4: 71528.
  • 35
    Jeremias I, Kupatt C, Baumann B, et al . Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 1998; 91: 462431.
  • 36
    Leverkus M, Neumann M, Mengling T, et al . Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000; 60: 5539.
  • 37
    Eggert A, Grotzer MA, Zuzak TJ, et al . Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001; 61: 13149.
  • 38
    Fulda S, Kufer MU, Meyer E, et al . Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001; 20: 586577.
  • 39
    Hinz S, Trauzold A, Boenicke L, et al . Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene. 2000; 19: 547786.
  • 40
    Jones DT, Ganeshaguru K, Mitchell WA, et al . Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol. 2003; 121: 71320.
  • 41
    Clancy L, Mruk K, Archer K, et al . Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA. 2005; 102: 18099104.
  • 42
    Rossin A, Derouet M, Abdel-Sater F, et al . Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J. 2009; 419: 18592.
  • 43
    Cuiffo B, Ren R. Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood. 2010; 115: 3598605.
  • 44
    Merino D, Lalaoui N, Morizot A, et al . Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006; 26: 704655.
  • 45
    Mahalingam D, Natoni A, Keane M, et al . Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer. 2010; 102: 75464.
  • 46
    Lemke J, Noack A, Adam D, et al . TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med. 2010; 88: 72940.
  • 47
    Guo F, Sigua C, Tao J, et al . Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Research. 2004; 64: 25809.
  • 48
    Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Research. 2008; 28: 85564.
  • 49
    Rosato RR, Almenara JA, Coe S, et al . The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007; 67: 9490500.
  • 50
    Tazzari PL, Tabellini G, Ricci F, et al . Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 2008; 68: 9394403.